Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Lidak Pharm. [LDAKA] -- Ignore unavailable to you. Want to Upgrade?

To: Henry Volquardsen who wrote (783)	1/4/1998 12:27:00 AM
From: Analog Kid	Respond to of 1115

Thanks Henry and John for responding. I was just expressing my (negative) gut feelings, my field is computing and not biotech so I have no background in this stuff, plus this is the 1st and only biotech I've ever invested in (bought my first shares in 94 on an exuberant recommendation in BI research). Henry is right that the (lack of) efficacy of acyclivir contradicts my thesis on psychosomatic influence. There just seems to be something fishy, I'm holding on to my shares nonetheless because we are at the last leg of this race and hopefully Lidak will get FDA approval, in which case the potential upside is enormous. I also find the LMI technology very exciting, again I have no background in this stuff but the discussion in the 95 (I think) annual report on how this technology works sounded cool. Analog Kid (Telebob, I was referring to the omission of placebo numbers in the recent press release on the NDA filing)